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doi:10.1016/j.ejvs.2009.05.008Abstract Technical advances have seen the rapid adoption of genomics and multiplex
genetic polymorphism identification to research on vascular diseases. The utilization of pro-
teomics for the study of vascular diseases has been limited by comparison. In this review we
outline currently available proteomics techniques, the challenges to using these approaches
and modifications which may improve the utilization of proteomics in the study of vascular
diseases.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Common vascular diseases, including atherosclerosis and
aortic aneurysm appear to result from interactions between
environmental risk factors and genetic predisposition which
exacerbate normal ageing processes. Mechanisms under-
lying these diseases include inflammation, alterations of
the vascular extracellular matrix and dyslipidaemia.
Changes in protein expression are a feature of pathological
progression and drive such alterations. Inflammation, for
example, is determined by the expression of adhesion7 47961417; fax: þ61 7
@jcu.edu.au (J. Golledge).
ty for Vascular Surgery. Publishemolecules, chemokines and pro-inflammatory cytokines.
Understanding the protein profiles associated with
different vascular diseases may help to improve disease
management in a number of areas including diagnosis,
prognosis and treatment.
Traditionally, identification of new disease-associated
proteins relied on hypothesis-led approaches, using tech-
niques such as ELISA and western blotting to investigate
expression of individual candidates. However, the relatively
recent development of techniques, including two-dimen-
sional electrophoresis in 1975,1 which enablemore complete
protein profiling have given rise to a discipline known as
‘‘proteomics’’, with potential to investigate protein
expression in response to endogenous andexogenous stimuli.
Using a suite of sample preparation, fractionation, separa-
tion and analysis tools a modern proteomics facility cand by Elsevier Ltd. All rights reserved.
Proteomics and Vascular Disease 347perform quantitative ‘differential display’ experiments
comparing cohorts of control and disease samples, high-
lighting molecules directly related to and/or indicative of
disease processes (Fig. 1). Whilst similar data can be gained
from gene expression studies, mRNA levels do not always
reflect protein expression and cellular phenotype.2 Thus,
proteomics provides data not easily obtained from other
post-genomic technologies (Fig. 2).3 Consequently, proteo-
mic techniques have been applied to wide variety of organ-
isms including plants, bacteria, fungi, and metazoa. In
a medical context, proteomic investigations have the
potential to uncover proteins of therapeutic and diagnostic
potential. However, despite ongoing endeavors, proteomicFigure 1 Standardised proteomics workflow. In a typical proteo
simplify downstream analyses. Proteins of interest are commonly
computer-aided database searches. Once identified, protein know
between treatments (relative quantification), or compared to an
Examples of the techniques available to perform each step are proscience has yet to provide a significant breakthrough in this
area, with many putative markers failing during validation.
In this review we outline proteomic techniques and discuss
current technical challenges and likely future
developments.Proteomic techniques
The Human Proteome Organisation (HUPO) defines a protein
as a complex molecule made up of one or more peptide
chains (a peptide consisting of two or more chemically-
linked amino acids), which perform a wide variety ofmics experiment, crude protein mixtures are fractionated to
investigated using mass spectrometry and identified following
n proteins can be quantified by comparing relative expression
internal standard of known quantity (absolute quantification).
vided. Definitions of acronyms are provided in Table 1.
Figure 2 Overview of cellular processes, and modern technologies available for their study. Definitions were sourced from the
Human Proteome Organisation (http://www.hupo.org/overview/glossary/), a the Human Metabolome Project (http://www.
metabolomics.ca/),b and a published article by Gomase and Tagore,3 (detailed in references).
348 J.V. Moxon et al.functions and are essential to the life of the cell (http://
www.hupo.org/overview/glossary/). Further definitions of
some common terms used in proteomics are provided in
Table 1.
Proteins are encoded by the genome, with each open
reading frame giving rise to an average of 6e7 protein
products. Thus, it is estimated that the human genome
comprising of 23,000e40,000 genes may give rise to up to
one million proteins, in addition to approximately 600,000serum immunoglobulins with slight variations in epitope
binding regions.4e6 However, protein structure is not
limited to genetic coding as post-translational modifica-
tions (PTMs) such as oxidation, phosphorylation and glyco-
sylation are performed throughout cellular metabolism,
and cannot be predicted by gene analysis. PTMs alter
protein function, and consequently have pathological
significance. For example the, matrix gamma-carbox-
yglutamate protein (MGP) is a known inhibitor of
Table 1 Glossary of common proteomics terms
Term Definition
ESI ElectroSpray Ionisation. A method of ionization whereby proteins or peptides are carried by a stream of volatile liquid to an emitter
carrying a high voltage. The liquid is sprayed from the emitter and the liquid evaporated, leaving the charged peptides or proteins to
be drawn into the mass spectrometer for analysis. Electrospray is advantageous in the analysis of peptides and proteins as multiply
charged ions are created which can be discriminated from singly-charged ions which are often contaminants
High-throughput proteomics The analysis of many protein samples in a short space of time.
MALDI Matrix Assisted Laser Desorption Ionisation. A method of ionizing proteins or peptides whereby proteins are mixed with a chemical
matrix and targeted by a laser. The matrix absorbs energy from the laser and is ionized, carrying singly-charged peptides into the gas
phase for MS analysis.
Mass spectrometry (MS) The analysis of gas phase ions (often peptides in the case of proteomics), to determine mass and charge of the intact molecule, or
component parts
PMF Peptide Mass Fingerprint. The profile of spectral peaks generated following mass spectrometry which documents the mass of ions
within a sample.
Reverse-phase chromatography The process whereby molecules in the liquid phase are separated by their hydrophobic properties.
Secretome A sub-set of proteins secreted from a cell, tissue or organism
SELDI Surface-Enhanced Laser Desorption Ionisation. A method of ionizing proteins or peptides whereby peptides are prefractionated by
reverse-phase chromatography and bind to a specialist chip. Bound proteins are exposed to a laser and are ionized into the gas phase
for MS analysis.
Shotgun proteomics The process of identifying molecules through MS analysis of a crude protein/peptide mixture prefractionated in one or two-dimensions
by chromatographic techniques.
TOF Time Of Flight. A method of measuring the mass of an ion in mass spectrometry, determined by the time taken for an ion to travel
a vacuum tube, and reach a detector.
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Table 2 Examples of Gel-based vascular proteomic investigations
Protein source Example of findings
Serum Serum analysis to determine effect of dietary fish oil on circulating biomarkers of inflammation: Sera treated to remove abundant proteins then
analysed via 2D-PAGE, gel analysis software, peptide mass fingerprinting and peptide sequencing. Fish oil supplementation caused a reduction in acute
phase proteins compared to sunflower oil controls, suggesting a reduction in inflammation. Serum levels of apolipoprotein A1 were also down
regulated following fish oil supplementation.8
Tissue Comparative analysis of proteins expressed by stable/unstable atherosclerotic plaques: Stability of carotid artery plaques assessed histochemically
and soluble proteins extracted. Analysis via 2D-PAGE, gel analysis software and peptide mass fingerprinting. Unstable plaques expressed higher
concentrations of ferritin (light subunit), superoxide dismutase 2 and fibrinogen D, and lower concentrations of GST, Rho GDP-Dissociation inhibitor 1,
annexin, HSP20 and HSP27.9
Cells Identification of proteomic signatures of platelet activation: Analysis of low-molecular weight soluble cellular proteins using surface-enhanced laser
desorption ionisation time of flight (SELDI-TOF) MS. Spectral profiles from resting platelets revealed a characteristic peak pattern when compared to
cells activated through shear stress, or exposure to adenosine diphosphate (ADP)- or thrombin receptor activation peptide. Analysis of ADP-stimulated
platelets isolated from patients receiving clopidogrel revealed a similar spectral profile to resting cells, demonstrating drug efficacy.10
Cultured cells Analysis of cultured neonatal rat VSMCs following homocysteine induced proliferation: Analysis of soluble proteins via 2D-PAGE, gel analysis
software and peptide mass fingerprinting. Homocysteine treated cells expressed higher concentrations of WDR1 protein, calreticulin, pyruvate kinase
M2, vimentin, aldose reductase and triose phosphate isomerise. Down regulation of lamin C and LIM and SH3 protein 1.11
Analysis of protein expression by human umbilical vein endothelial cells (HUVEC) following digoxin-induced toxicity: Cultured HUVEC proteins
extracted and analysed via 2D-PAGE, gel analysis software and peptide sequencing. Pro-apoptotic digoxin treatment results in differential expression
of 9 proteins (upregulation of ATP synthetase, Lamin A, Cystatin A, Succinyl Co-A, nuclear riboprotein H3, Proteasome subunit 5; down regulation of
HSP60, electron transfer flavoprotein, profilin-1). Induced overexpression of HSP60 reduced digoxin-induced apoptosis suggesting that HSP60 is
important in cellular protection.12
Analysis of protein expression by HUVECs during replicative senescence to investigate cellular ageing: Soluble proteins expressed by cultured
HUVECs extracted and analysed via DiGE, gel analysis software, peptide sequencing and western blot. Senescence seen to be accompanied by
expression of proteins involved in cellular stress mechanisms and protein biosynthesis. Reductions in the expression of DNA repair/maintenance
proteins is hypothesised to underpin observed nuclear degradation and cytoskeleton disruptions.13
Abbreviations: ADP: adenosine diphosphate, GST: glutathione transferase, HSP: heat shock protein, HUVEC: human umbilical vein endothelial cells, VSMC: vascular smooth muscle cell.
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Proteomics and Vascular Disease 351cardiovascular calcification, and the uncarboxylated form
(uMGP) has been shown to accumulate within calcified
tissue. Consequently, circulating uMGP is a proposed
biomarker for vascular calcification, with low titres a risk
factor for vascular calcification.7 Accordingly, investiga-
tions into the expression of proteins and PTMs in disease
states have potential to generate data of clinical
significance.Gel-based proteomics
Two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE), separating proteins according to charge (first
dimension), and molecular weight (second dimension), can
profile thousands of polypeptides within a sample, enabling
non-hypothesis-led investigations. Changes in protein
expression, evidenced through alterations in spot density,
are determined through computer-aided comparisons of 2D
profiles produced from diseased and control tissues and
highlight proteins specifically expressed in response to
disease. Spots of interest can be directly excised from gels
for identification through mass spectrometry (MS). Many of
the published vascular proteomics investigations have been
conducted using a gel-based format (Table 2).8e13 For
example, gel-based investigations performed by Urbonavi-
cius et al. (2008), confirm the role of oxidative stress in
aneurysm rupture, confirmed by the upregulation of stress-
response proteins when compared to non-ruptured
controls.14
Criticisms of 2D-PAGE include gel-to-gel variability,
inability to analyse highly basic and hydrophobic proteins,
poor visualization of very high- or very low-molecular
weight proteins, under-representation of weakly-expressed
proteins, and a lack of easy automation.15e19 Some of these
criticisms relate to the difficulty of good sample prepara-
tion, consequently poor samples are the cause of most poor
2D gels. However, 2D-PAGE is the only technique capable of
simultaneously resolving thousands of post-translationally
modified proteins due to, influence such modifications
exert on the migration of proteins during electrophoresis
which is easily visualized following 2D-PAGE. For example,
oxidized 1-Cys peroxiredoxin expressed within the aortas of
apolipoprotein E (Apo E/) deficient mice has a more
acidic charge than the form expressed by Apo Eþ/þ
controls, and migrates to a different position following 2D-
PAGE.20 Thus, gel-based investigations generate data diffi-
cult to obtain from other proteomic techniques, supporting
their continued use.
The introduction of increasingly sensitive protein stains
has enhanced the analytical power of 2D-PAGE. The
development of the difference gel electrophoresis (DiGE)
technique,21 in which fluorescent cyanine dyes are cova-
lently bound to lysine residues within sample proteins,
enables analysis of multiple samples within the same gel.
Furthermore, DiGE protein expression is compared to
a known internal standard, reducing gel-to-gel variation.
Currently, the simultaneous analysis of 2 samples (2-plex) is
possible, and is particularly useful when comparing protein
expression in the same individual at different time points or
following interventions, such as a drug treatment.
However, the application of DiGE to vascular investigationshas been limited, possibly due to the cost of compatible
reagents and specialized equipment.13,22
MS-based proteomics
MS is the central protein identification technique in almost
all proteomic investigations, with the exception of chip
array experiments. A mass spectrometer measures the mass
of ions within a sample, and comprises an ion source,
a mass analyzer which measures the mass-to-charge ratio
(m/z) of the ions, and a detector to record the frequency of
ions at each m/z value.23 In proteomic studies MS analysis is
commonly conducted on ionized peptides yielded from
enzymatic digestion of sample proteins. MS analysis enables
quantitative investigation into complex protein samples
regardless of the hydrophobicity, charge and size of
constituent components,24 without the need for as large
a quantity of sample proteins needed for gel-based
approaches. With this in mind, MS-based proteomic
approaches are useful when working with scarce or protein-
poor samples. The commercialisation of reagents for MS-led
investigations has improved access to these approaches.
For example, protein labeling techniques using stable
‘heavy’ isotopes (e.g. 15N, 2H, 18O and 13C), generate
a detectable shift from native molecular mass, to distin-
guish between experimental treatments.25e30 These tech-
niques have increased the multiplex capabilities of MS,
enabling the simultaneous analysis of several samples.
Stable isotopes can also be used to supplement cell culture
media, or animal chow to enable MS-based investigations of
protein expression in actively metabolising cells and tissu-
es.31e34 However, MS-based methods do not readily provide
information about PTMs which are plainly visible on 2D gels.
An online supplement discussing the principles of MS is
available.
Protein micro- and macro-array
Protein arrays are equivalent to gene arrays, and assess
relative protein expression within sample tissue. Such
assays usually consist of specific antibodies immobilized on
a chip or membrane which are incubated with proteins
extracted from diseased or control samples, enabling
antigen/antibody complexes to form. This approach can be
used as a means to fractionate crude samples for further
analysis (for example in SELDI-MS), or protein binding can
be quantified, reflecting antigen levels within patient
samples permitting direct investigation into protein
expression. The investigative potential of this approach is
limited to commercially available antibody panels, thus
protein microarrays are more suited to hypothesis-driven
research than novel protein discovery per se. However, the
two approaches are compatible as proteins discovered
through non-biased investigations can be validated in large
cohorts using the microarray format, providing that
appropriate antibodies are available. It is expected that
future developments of this technique will allow more
comprehensive protein assessment; however, the range of
protein isotypes, fragments and modifications expressed
in vivo present considerable challenges for true global
analysis using protein arrays.
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Sample complexity
Examination of whole tissue samples is complicated by the
presence of abundant proteins which mask more conserva-
tively expressedmolecules. This is particularly true of serum
or plasma, in which albumin accounts for 55% total protein
(normal concentration range 35e50 mg/ml). In contrast
other proteins are present in much lower concentrations
(e.g. interleukin 6, normal concentration range 0e5 pg/
ml).35e38 Thus, plasma protein expression is estimated to
span 10 orders of magnitude, often referred to as the
‘dynamic range’ of the sample. Such variation cannot be
visualised as current techniques capture a dynamic range
spanning of 4e5 orders of magnitude and only abundant
molecules will be profiled from crude samples.35,39 Similarly,
analysis of vascular tissue is complicated by cellular
heterogeneity, favouring proteins expressed by dominant
cell types, where the dynamic range spans at least 5e6
orders of magnitude.17 Weakly-expressed molecules can be
enriched by depleting dominant proteins. However, this can
introduce experimental error by removing protein
complexes, or misrepresenting genuine variations in the
expression of abundant proteins.36,40
Sample complexity can be reduced by studying a sub-
group of proteins expressed within tissues using physical
extraction techniques such as laser microdissection to
isolate specific cells from tissue preparations,25,41
biochemical methods,22,42 or cellular approaches to identify
proteins secreted from cell lines or tissue explants (the
secretome). Secretome analysis is attractive since soluble
secreted proteins are more amenable to proteomic profiling
than their hydrophobic counterparts. Furthermore, such
studies highlight proteins which may enter the bloodstream,
revealing a panel of putative circulating biomarkers.
Secretomeanalysis iscommonlyconducted through in vitro
incubation of tissue explants,43e45 or cell lines,46,47 and 2D-
PAGE/MS analysis of culture fluid. However, in vitro culture
inevitably results in some degree of sample deterioration
which releases cellular proteins into the culturemedia. Under
typical conditions cellular proteins cannot be differentiated
from secretedmolecules at the gel level, potentially resulting
in the discovery of false biomarkers. Truly secreted proteins
can be putatively revealed by analyzing proteins to detect
amino acid motifs involved in protein secretion following MS
identification.48 Suchanalysesgeneratemore robustdatasets,
although extensiveMS investigations are necessary before the
truly secreted proteins can be differentiated.Modifications to
cell culture andproteomic techniques facilitate identification
of secretedproteins, offeringanalternative toexhaustiveMS/
bioinformatic analysis. Radiolabelled amino acids (e.g. 35S-
methionine), can be used as metabolic tags are detectable at
the gel level; non-labelled proteins can be considered as
degradation products and discounted from further analysis.49
Potential drawbackssuchas theneedfor specialist radioactive
facilities, and radiation-induced alterations in protein
expression can be alleviated by using stable isotopes, and the
stable isotope labelling by amino acids in cell culture (SILAC)
technique has been used to characterise biomarkers secreted
from a variety of tissues.50e52Experimental complexity
Experimental design
There are currently no formalized guidelines for the design
of proteomic experiments and data presentation, and early
proteomic investigations often documented two-dimen-
sional protein profiles or mass spectra. Such analyses are no
longer considered suitable for publication, and protein
identification is essential. The recent publication of the
minimum information about a proteomics experiment
(MIAPE) document by HUPO’s protein standards initiative
(HUPO PSI), has provided more stringent guidelines for
reporting proteomic data.57 Whilst these suggestions are
not concrete, many of the leading journals in this field
employ MIAPE criteria, insisting on the provision of meta-
data to increase confidence in the proteomic experiment
and subsequent analyses (e.g. MS and statistics). Increased
visibility of metadata has stimulated the development of
open-access online repositories such as the proteomics
identifications database (PRIDE),53,54 which capture MS
identifications and annotations from proteomics investiga-
tions in a standard format. It is envisaged that such
repositories will act as a valuable research tool, whilst
upholding HUPO PSI standards and vocabulary.
As with other scientific methodologies, the MIAPE
document emphasises the need for replication to generate
reliable data. Calculation of suitable sample sizes can be
problematic, and depends on the complexity of the pro-
teomes to be analysed and the level of variation antici-
pated between treatments. Calibration experiments using
standard protein mixtures of similar complexity to tissues
of interest may help to ensure suitable replication.55,56
Alternatively, the use of power calculations can help
determine suitable sample sizes.57 In the case of gel-based
investigations, a minimum of 5 replicates per treatment has
been recommended, with modifications to established
statistical analyses to limit the number of false protein
spots observed.58 Whilst this improves confidence in
experimental data, replication in medical experiments may
be problematic due to the paucity of suitable samples.
Similarly, the availability of control tissue can limit
potential investigations, especially in vascular experiments
where healthy vasculature is not routinely sampled.
Samples recovered at autopsy may increase experimental
variation through physiological changes post-mortem and
differences in tissue collection protocols. Furthermore,
post-mortem samples are of limited use when investigating
chronic diseases such as atherosclerosis, where variables
including age and prolonged exposure to therapeutic
compounds may complicate case/control matching. Small
quantities of tissue such as aneurysm neck which can be
removed from patients during surgical repair will match
experimental samples and may be used as controls, but are
unlikely to represent truly healthy vasculature despite
being visibly free of complications.
Reproducibility
Biological and technical variations can affect the repro-
ducibility of proteomic investigations although commerci-
alisation of common proteomic consumables has
Proteomics and Vascular Disease 353contributed towards increased reproducibility and experi-
mental robustness. The development and standardization
of sample preparation protocols appropriate to the exper-
imental tissues represent the greatest challenge to effec-
tive and reproducible proteomic profiling. Successful
proteomic investigations rely on understanding the sample
that is to be analysed and knowledge of how to extract and
solubilise the desired proteins whilst eliminating contami-
nants. Sample preparation can appear daunting primarily
because diversity within even the simplest proteome
cannot be captured by any single extraction and separa-
tion. Over the past decade, fractionation has been widely
adopted to reduce sample complexity and enable analysis
of weakly-expressed proteins. Diversity in sample prepa-
ration is reflected by scientific literature.59,60 Despite this,
inter-laboratory variation remains an issue, as discussed by
Callesen et al. (2008), who report that only 25% of reported
biomarker peaks for breast cancer could be detected by
other research groups following SELDI-MS.61Protein identification
Molecular identification is commonly achieved after MS
analysis by searching electronic databases containing
protein and/or translated gene sequences. Database
searches generate putative identifications based on
homology between experimental peptide sequences or
fragmentation patterns, to those of known molecules.
Putative identifications are quantifiedby assigning statistical
scores (such as statistical error) to reflect the surety of each
search; identifications are only accepted when the calcu-
lated error falls below accepted thresholds.17 This approach
is only possible when databases contain data relating to the
experimental proteins and relies on comprehensive data-
sets. In the case of medical investigations, MS-based protein
identification is facilitated by the completion of the human
genome project, and increased availability of genomic data
for common animal models. However, identification of
weakly-expressed polypeptides remains challenging in the
absence of a PCR equivalent for proteins.
Whilst desirable for publication, protein identification
may not always be needed for clinical applications, espe-
cially where disease-state protein profiles are distinctly
different to healthy controls. For example, MS analysis of
low-molecular weight proteins expressed by platelets
reveals distinctive changes in spectral peaks which discrim-
inate resting platelets from those aggregated by ADP or
thrombin-activator peptide (sensitivity 65%, specificity 89%).
Platelets isolated from patients receiving clopidogrel
therapy show a 70% reduction in ADP-induced aggregation,
this is mirrored by a similar MS profile to resting platelets.10
Such analyses may be of particular benefit when assessing
patient response to medication, highlighting appropriate
therapeutic regimes. Similarly, case-control comparisons of
urine protein profiles in coronary artery disease (CAD)
demonstrated increased expression of a panel of 17 poly-
peptides in CAD patients. Using this pattern as a diagnostic
tool, von Zur Muhlen et al. (2009) reported 81% sensitivity
and 92% specificity using samples from 26 CAD patients and
12 controls in a blinded study. However, later analyses
revealed a similar protein profile in patients with chronicrenal failure suggesting that renal damage may disturb the
urine proteome and complicate proteomic analysis.62
Future directions of proteomics
Proteomic techniques document the expression of mole-
cules which directly influence cell phenotype, and there-
fore provide data of clinical relevance. These techniques
can be applied to a wide variety of organisms and biological
samples, and can be applied to investigate protein
expression in vitro or in vivo. Proteomic tools permit
analysis of thousands of proteins and their PTMs and enable
non-biased appraisals of the molecular biology of disease
states, highlighting molecules which may be overlooked in
hypothesis-driven scenarios. As described above, proteomic
science is a relatively recent development. Currently pro-
teomics receives many criticisms, notably low reproduc-
ibility evidenced by gel-to-gel and inter-laboratory
variation. Despite this, it is likely that these issues will
diminish as protocols and reporting requirements become
standardised and are universally applied. Identification of
weakly-expressed molecules via MS remains problematic,
although techniques such as western blotting may be used
to overcome this challenge.
The application of proteomics to vascular disease is at an
early stage, and without subsequent downstream analyses,
proteomic experiments merely provide lists of protein data
with little practical value. Proteomic investigations generate
large datasets which require expertise for meaningful anal-
ysis, especially in the case of large or complex experiments.
The continued use of proteomics has provided the stimulus
for improvements in data visualization, contributing to the
establishment of bioinformatics as a specialist field.
Currently, it is becoming common for proteomic data to be
displayed as interaction networks, highlighting associations
(e.g. synchronous up/down-regulation) between identified
molecules.63,64 This is of particular benefit when investi-
gating disease mechanisms, or therapeutic pathways. The
most routine application of proteomic techniques in vascular
medicine is to discover biomarkers of diagnostic, therapeutic
and prognostic potential. However, protein identifications
generated by proteomic techniques remain putative,
requiring validation through more established approaches
including ELISA, western blotting and immunohistochem-
istry, using reliable antibodies. Furthermore, in order to
assess biomarker performancemolecules of interest must be
validated in large patient populations using high-throughput
techniques which is time consuming and limited by access to
large patient cohorts.
The investigative power of proteomics is greatly magni-
fied when combined with other post-genomic techniques.
Combined proteomic and metabolomic analyses provide
direct evidence of the effect of protein expression on
cellular processes. Using this approach, Perlman et al. (2009)
investigated the cardioprotective mechanisms following
nitrate exposure. Nitrate administration resulted in a short-
lived increase in cardiac nitrate levels, but substantial
elevations in cardiac ascorbate oxidation. This was accom-
panied by significant improvements in cardiac contractile
recovery following ischemia-reperfusion after pre-
conditioning with low (0.1 mg/kg) or high (10 mg/kg) nitrate
doses. Proteomic analysis of cardiac mitochondria revealed
dose-dependant PTM of isoforms of 3 proteins involved in
354 J.V. Moxon et al.serine/threonine kinase signaling, anti-oxidant protection
and cell metabolism. This led the authors to suggest that
a similar mechanism may underpin the cardioprotective
value of physical exercise and a diet containing nitrite/
nitrate-rich foods.65 Such systemic strategies have been
successfully employed in other biological situations,
although relatively few vascular investigations have
embraced this multi-omics approach. Thus it seems likely
that vascular medicine will greatly benefit from the future
application of proteomics in a ‘multi-omics’ context.
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